Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-004-1502-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge.
Int J Mol Sci
December 2024
Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania.
Starting from the metabolic profile of type 2 diabetes mellitus (T2DM), we hypothesized that the mechanisms of ¹³¹I-induced cardiotoxicity differ between patients diagnosed with differentiated thyroid cancer (DTC) with/without T2DM, with metformin potentially acting as a cardioprotective agent by mitigating inflammation in patients with T2DM. To address this hypothesis, we quantified, using ELISA, the serum concentration of several key biomarkers that reflect cardiac injury (NT-proBNP, NT-proANP, ST2/IL-33R, and cTn I) in 74 female patients with DTC/-T2DM and 25 with DTC/+T2DM treated with metformin. All patients received a cumulative oral dose of I exceeding 150 mCi (5.
View Article and Find Full Text PDFA Belgian single centre outcome study of radioiodine treatment in adolescents with Graves' disease.
Sci Rep
December 2024
Division of Paediatric Endocrinology, Vrije Universiteit Brussel, UZ Brussel, Laarbeeklaan 110, Brussels, 1090, Belgium.
Up to 80% of children/adolescents with Graves' disease (GD) may require second-line treatment with either surgery or radioactive iodine (RAI) therapy after treatment with antithyroid drugs. These interventions aim to induce permanent hypothyroidism, but are not always successful. We aimed to evaluate the initial success rate (within the first year) of RAI treatment and its determining factors as second-line treatment in teenagers with GD.
View Article and Find Full Text PDFRadiofrequency Ablation for Solitary Autonomously Functioning Thyroid Nodules: Multicenter Study from Latin America.
Thyroid
December 2024
Oncology Center, Oswaldo Cruz German Hospital, São Paulo, Brazil.
Autonomously functioning thyroid nodules (AFTNs) represent ∼5% of all thyroid nodules and often necessitate definitive treatments such as surgery or radioiodine (I), both of which have inherent risks. Radiofrequency ablation (RFA) has emerged as an effective and safe therapeutic option for managing AFTNs. This study aims to assess the effectiveness and safety of RFA for solitary AFTNs in various countries across Latin America.
View Article and Find Full Text PDFAssessment of surface contamination of low-dose radioactive iodine (131I) treatment container.
Nucl Med Commun
December 2024
Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Pocheon-si.
With the advancement of radiotherapy technology in the medical field, the amount of radioactive waste has rapidly increased, and the International Atomic Energy Agency (IAEA) has proposed waste deregulation standards based on individual dose, collective dose, and nuclide concentration. The purpose of this study is to define the standard period (1 day) required to measure collected radioactive waste using direct and indirect methods with a radioactivity meter, ensure that the radiation dose remains below the allowable level, and transport the waste safely. In this study, 131I low-dose (30 mCi) radioactive waste discarded after radioiodine treatment at a medical institution was collected, and a measuring container was prepared to measure radioactivity concentration according to IAEA standards.
View Article and Find Full Text PDFEfficacy of a fixed low dose of radioactive iodine in the treatment of Graves' disease in Sub-Saharan Africa.
Hell J Nucl Med
December 2024
Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Objective: Graves' disease represents 60%-90% of all causes of thyrotoxicosis in different regions of the world. Thyrotoxicosis contributes approximately 66% to thyroid disorders in South Africa and of those Graves' disease contributes about 34%. In most Sub-Saharan African countries, Graves' disease is managed mainly with medical treatment, due to a lack of or poor access to other means of treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!